Geron Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 4/6
Geron şirketinin toplam hissedar öz sermayesi $225.9M ve toplam borcu $119.5M olup, bu da borç-öz sermaye oranını 52.9% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $570.5M ve $344.7M dir.
Anahtar bilgiler
52.93%
Borç/özkaynak oranı
US$119.55m
Borç
| Faiz karşılama oranı | n/a |
| Nakit | US$357.92m |
| Eşitlik | US$225.87m |
| Toplam yükümlülükler | US$344.67m |
| Toplam varlıklar | US$570.54m |
Son finansal sağlık güncellemeleri
Geron (NASDAQ:GERN) Is Using Debt Safely
Dec 15
Here's Why Geron (NASDAQ:GERN) Can Manage Its Debt Despite Losing Money
Aug 07Is Geron (NASDAQ:GERN) A Risky Investment?
Apr 17We're Hopeful That Geron (NASDAQ:GERN) Will Use Its Cash Wisely
Feb 27Is Geron (NASDAQ:GERN) Using Too Much Debt?
Oct 28Does Geron (NASDAQ:GERN) Have A Healthy Balance Sheet?
Jul 12Recent updates
GERN: Refined Risk And Earnings Assumptions Will Support Upside Through 2026
Analysts have trimmed their Geron price target by $1, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E. These changes keep fair value at $5.00 while slightly adjusting the risk and earnings profile behind that target.GERN: Future Myeloid Franchise And 2026 Outlook Will Drive Upside
Analysts have trimmed their 12 month price target for Geron by $1, citing updated assumptions on discount rate, revenue growth, profit margin, and future P/E that modestly adjust their valuation framework. Analyst Commentary Even with the trimmed 12 month target, bullish analysts still frame the recent move as a tweak to their model rather than a shift in their overall view on Geron.GERN: Future Myeloid Franchise And 2026 Revenue Guidance Will Support Upside
Analysts have reduced their price target on Geron by $1 to $5, citing updated assumptions around discount rate, revenue growth, profit margin and future P/E that remain consistent with their broader valuation framework. Analyst Commentary Bullish analysts are treating the revised US$5 price target as a confirmation of their existing constructive view rather than a reversal.Geron: Minimal Sales Growth But A Potential Run-Up Ahead
Mar 19
GERN: Future Profit Upside Will Be Supported By Conservative Forecast Reset
Analysts have trimmed their price target on Geron by $1, reflecting slightly more conservative assumptions for revenue growth, profit margins, and future P/E, while maintaining the same fair value estimate and making only a modest adjustment to the discount rate. Analyst Commentary Recent Street research reflects a slightly more cautious stance on Geron, with a trimmed price target tied to updated assumptions on growth, margins, and the P/E used in models.GERN: Future Profit Expansion Will Be Driven By Margin Improvement Potential
Geron's updated narrative reflects a modestly higher analyst fair value estimate of about $3.40, with analysts pointing to a slightly lower discount rate, lower projected revenue growth, a higher profit margin, and a reduced future P/E assumption following recent Street research that included a $1 trim to the TD Cowen price target. Analyst Commentary Analysts are updating their views following the recent Street research that trimmed a key price target by US$1, which fed into the modest reset of the fair value estimate to about US$3.40.GERN: Future Myeloid Franchise And 2026 Guidance Will Drive Upside
Analysts have trimmed their price target on Geron by US$1. This reflects updated assumptions around discount rate, revenue growth, profit margin and future P/E that slightly reshape their risk and return expectations for the stock.Geron Corporation's (NASDAQ:GERN) Prospects Need A Boost To Lift Shares
Feb 03GERN: Future Myeloid Franchise Progress Will Drive Upside Potential
Analysts have nudged their price target on Geron to US$5.00, reflecting updated assumptions around revenue growth, profit margins and future P/E. These revisions are broadly consistent with prior estimates but modestly refined in their models.GERN: Future Myeloid Indications Will Drive Upside Despite Safety Trade Offs
Analysts have reaffirmed their price target on Geron at US$5.00, reflecting updated views on discount rates, revenue growth, profit margins and future P/E assumptions. What's in the News New data from the 67th American Society of Hematology 2025 Annual Meeting in Orlando highlighted interim results from an investigator-sponsored Phase 2 study of imetelstat in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia who had limited options after hypomethylating agent therapy (Key Developments).GERN: Future Myeloid Malignancy Indications Will Drive Upside Despite Safety Risks
Analysts have modestly raised their price target on Geron to align with a slightly lower discount rate and incremental improvements in projected revenue growth, profit margins, and future valuation multiples, lifting their fair value estimate to about 5.00 dollars per share. What's in the News New data from the 67th American Society of Hematology 2025 Annual Meeting highlighted interim Phase 2 results for imetelstat in advanced myelodysplastic neoplasms and acute myeloid leukemia patients who failed or could not tolerate hypomethylating agents, reinforcing Geron’s focus on high unmet-need myeloid malignancies (Key Developments).Geron (NASDAQ:GERN) Is Using Debt Safely
Dec 15GERN: Expanded Blood Cancer Indications Will Drive Upside Despite Safety Concerns
Analysts have trimmed their price target on Geron from approximately 6.00 dollars to 5.00 dollars, citing a higher perceived risk profile and more conservative expectations for revenue growth and profitability. What's in the News New data from the 67th American Society of Hematology 2025 Annual Meeting highlighted Geron’s completion of the Part 1 dose escalation phase, establishing 8.9 mg/kg IV every 4 weeks as the recommended imetelstat dose with ruxolitinib in combination studies (Key Developments) Interim results from an investigator sponsored Phase 2 trial showed imetelstat activity in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia who had failed or could not tolerate hypomethylating agent therapy (Key Developments) RYTELO, Geron’s telomerase inhibitor, is now the first and only drug of its class approved by both the U.S. Food and Drug Administration and the European Commission for certain lower risk MDS patients with transfusion dependent anemia (Key Developments) Clinical trial safety data reported high rates of serious hematologic adverse events, including new or worsening Grade 3 or 4 thrombocytopenia in 65 percent of RYTELO treated MDS patients and Grade 3 or 4 neutrophil abnormalities in 72 percent, which underscores a complex benefit risk profile (Key Developments) Geron continues a pivotal Phase 3 IMpactMF trial in JAK inhibitor relapsed or refractory myelofibrosis and other studies in myeloid malignancies, while cautioning about regulatory, manufacturing, commercial execution, and post marketing commitment risks that could affect timelines and approvals (Key Developments) Valuation Changes Fair Value Estimate, reduced from approximately 6.0 dollars to 5.0 dollars, representing a moderate downward revision in long term valuation.GERN: Future Profit Expansion Will Drive Bullish Share Price Outlook
Analysts have lowered their price target for Geron from $3.43 to $3.33. They cite more conservative assumptions for revenue growth and profit margins as the reason for this adjustment.GERN: Stronger Profit Margins Will Drive Share Price Momentum Ahead
Narrative Update: Geron Analyst Price Target Adjustment Analysts have revised Geron's fair value estimate downward from $3.63 to $3.43. This change reflects updated assessments of revenue growth, profit margin, and forecasted price-to-earnings ratios.Geron Corporation's (NASDAQ:GERN) Business And Shares Still Trailing The Industry
Nov 04Aging Population Trends Will Expand Hematology Market Opportunity
Consensus analyst price targets for Geron remain unchanged at $3.62, as underwhelming initial sales and modest near-term expectations for Rytelo, coupled with concerns about commercial execution, weigh on sentiment and lead to sharply divergent outlooks such as Goldman Sachs' $1 target. Analyst Commentary Initial commercial launch of Rytelo has underperformed expectations.Here's Why Geron (NASDAQ:GERN) Can Manage Its Debt Despite Losing Money
Aug 07Geron Corporation's (NASDAQ:GERN) Shares Climb 30% But Its Business Is Yet to Catch Up
Jun 13Analysts Have Lowered Expectations For Geron Corporation (NASDAQ:GERN) After Its Latest Results
May 10
EU Approval And US Initiatives Will Expand Future Markets
European expansion with RYTELO's approval and launch could significantly boost revenue through international growth and increased market reach.Is Geron (NASDAQ:GERN) A Risky Investment?
Apr 17Geron Corp.: A Compelling Potential Buying Opportunity Thanks To Bearish Comments
Mar 31Geron Corp: How Concerned Should We Be About Rytelo Sales?
Mar 17Risks Still Elevated At These Prices As Geron Corporation (NASDAQ:GERN) Shares Dive 45%
Mar 12We're Hopeful That Geron (NASDAQ:GERN) Will Use Its Cash Wisely
Feb 27Geron: Rytelo's Market Share Concerns Justified As 3L Dominates Early Sales
Feb 26Geron Corporation: Lackluster Share Price Performance Despite Reasonable Drug Launch
Feb 03Geron: A Post Earnings And Funding Announcement Assessment
Nov 07Is Geron (NASDAQ:GERN) Using Too Much Debt?
Oct 28Geron's Rytelo Gains Traction Despite Competitive Pressures (Rating Upgrade)
Aug 12Geron: Probabilistic And Modest Estimate Of Pricing For A Likely Acquisition
Jul 31Does Geron (NASDAQ:GERN) Have A Healthy Balance Sheet?
Jul 12Geron: Innovative Rytelo Enters A Challenging MDS Market
Jun 08Why We Think Geron Corporation's (NASDAQ:GERN) CEO Compensation Is Not Excessive At All
May 03Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: GERN 'nin kısa vadeli varlıkları ( $520.3M ) kısa vadeli yükümlülüklerini ( $111.5M ) aşıyor.
Uzun Vadeli Yükümlülükler: GERN şirketinin kısa vadeli varlıkları ( $520.3M ) uzun vadeli yükümlülüklerini ( $233.1M ) aşmaktadır.
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: GERN şirketinin toplam borcundan daha fazla nakiti var.
Borcun Azaltılması: GERN şirketinin borç/öz sermaye oranı son 5 yılda 11.4% seviyesinden 52.9% seviyesine yükseldi.
Bilanço
Nakit Pist Analizi
Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.
İstikrarlı Nakit Pisti: GERN şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.
Tahmini Nakit Akışı: GERN tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.
Sağlıklı şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/04 21:11 |
| Gün Sonu Hisse Fiyatı | 2026/05/04 00:00 |
| Kazançlar | 2025/12/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Geron Corporation 18 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Douglas Buchanan | Brean Capital Historical (Janney Montgomery) |
| Thomas Shrader | BTIG |
| Charles Duncan | Citizens JMP Securities, LLC |